CDRH Eyeing Drug Money, “True Dialogue” in User Fee Talks

article image
ARTICLE SUMMARY:

FDA device officials appear to be eyeing the big dollars tied to drug user fee programs with some envy, and other updates from the MDUFA V negotiations.

The device industry’s goal to keep FDA user fees close to current levels in the next round of the program (MDUFA V) is hitting a snag in early negotiation meetings with agency officials who are raising FDA drug user fees as a comparator.

×

This article is restricted to subscribers only.

To continue reading, select one of the options below:

Existing Subscriber?


Sign In to continue reading.


Need Multi-User Access?

Gain access for your entire organization.

Get Quote Check to see if your company already has access

Subscribe to Market Pathways:

Actionable intelligence exploring the people, challenges, and opportunities impacting the global medtech community.

Subscribe to Market Pathways
Sign up for All-Access

Join our global community with a subscription to both MedTech Strategist and Market Pathways for one low price.

All-Access

Questions?

We're here to help! Please contact us at: